Taking Aim at a Rare Type of Thyroid Cancer
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with...
Progress Against Cancer
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with...
A study finds that incidence of thyroid cancer rose by 169% between 1990 and 2017, and more news of...
Study: Thyroid cancer survivors – especially those diagnosed before age 40 – had elevated risk for several aging-related diseases....
About nine out of 10 U.S. thyroid cancer diagnoses are differentiated thyroid cancers; the FDA approval provides a new...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now